Urology News and Research RSS Feed - Urology News and Research

Urology is the field of medicine that focuses on the urinary tracts of males and females, and on the reproductive system of males. In men, the urinary system overlaps with the reproductive system, and in women the urinary tract opens into the vulva. In both sexes, the urinary and reproductive tracts are close together, and disorders of one often affect the other. The organs covered by urology include the kidneys, ureters, urinary bladder, urethra, and the male reproductive organs (testes, epididymis, vas deferens, seminal vesicles, prostate and penis).
Further Reading
Hitachi Aloka Medical announces release of Ultrasound Bone Densitometry System at ECR 2015

Hitachi Aloka Medical announces release of Ultrasound Bone Densitometry System at ECR 2015

Mr Minoru Yoshizumi, President of Hitachi Aloka Medical Ltd., Tokyo, Japan, is pleased to announce the release of EggQus, an extraordinary compact, portable Ultrasound Bone Densitometry System at the European Radiology Congress. Delegates will have the opportunity to see and test EggQus at the Hitachi Medical Systems booth 323, Expo C. [More]
New study assesses suicide risks in older, white males with advanced bladder cancer

New study assesses suicide risks in older, white males with advanced bladder cancer

Older, single white males with advanced bladder cancer have the highest suicide risk among those with other cancers of the male genitals and urinary system, researchers report. [More]
Endo International’s revenues increase $800 million to 37% in fourth quarter 2014

Endo International’s revenues increase $800 million to 37% in fourth quarter 2014

Endo International plc today reported fourth quarter 2014 revenues of $800 million, an increase of 37 percent compared to fourth quarter 2013 revenues of $585 million, including new product revenue from 2014 strategic M&A transactions. [More]
Taiho announces submission of TAS-102 MAA to EMA for treatment of mCRC

Taiho announces submission of TAS-102 MAA to EMA for treatment of mCRC

Taiho Pharma Europe Ltd., a subsidiary of Japan based Taiho Pharmaceutical Co., Ltd., announced that it has submitted a Marketing Authorisation Application to the European Medicines Agency for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug intended for use in the treatment of refractory metastatic colorectal cancer (mCRC). [More]
Study reports 10% reduction in overall C-section births in Portugal

Study reports 10% reduction in overall C-section births in Portugal

A new study reports a significant decline in the rate of cesarean section (C-section) births in Portugal. Findings published in Acta Obstetricia et Gynecologica Scandinavica, a journal of the Nordic Federation of Societies of Obstetrics and Gynecology, indicate a 10% reduction in overall C-section rates between 2009 and 2014, with a 14% reduction in state-hospitals during the same time period. [More]
Patients who receive chemotherapy after bladder cancer surgery demonstrate 30% lower risk of death

Patients who receive chemotherapy after bladder cancer surgery demonstrate 30% lower risk of death

Patients that received chemotherapy after bladder cancer surgery demonstrated an approximately 30% lower risk of death than those that underwent surgery alone, according to an analysis to be presented by researchers at the Icahn School of Medicine at Mount Sinai at the 2015 Genitourinary Cancers Symposium. [More]
FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years. [More]
Frailty assessment test can accurately predict complications after major operation

Frailty assessment test can accurately predict complications after major operation

Frailty has been used to predict how well a patient may recover from a major operation. Because frailty assessments are not routinely utilized in busy surgical practices, surgeons at Emory University School of Medicine in Atlanta have discovered that a short, approximately one-minute assessment can accurately determine how likely a patient is to have complications after an operation. [More]
AR-V7 status does not affect response to taxane chemotherapy in patients with mCRPC

AR-V7 status does not affect response to taxane chemotherapy in patients with mCRPC

Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). Treatment outcomes were largely similar for the 17 patients with AR-V7-positive prostate cancer and the 20 patients with AR-V7-negative disease included in this analysis. [More]
Actavis files ANDA to market Budesonide Extended-release Tablets

Actavis files ANDA to market Budesonide Extended-release Tablets

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Budesonide Extended-release Tablets, 9 mg. [More]
Taiho Oncology announces acceptance of TAS-102 NDA for review by FDA

Taiho Oncology announces acceptance of TAS-102 NDA for review by FDA

Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced the New Drug Application (NDA) for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), has been accepted for review by the U.S. Food and Drug Administration. [More]
Actavis obtains final approval from FDA for generic Subutex

Actavis obtains final approval from FDA for generic Subutex

Actavis plc today announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Reckitt Benckiser's Subutex (Buprenorphine 2 mg and 8 mg sublingual tablets). [More]
Research findings lay groundwork for improving treatment assessment for men with prostate cancer

Research findings lay groundwork for improving treatment assessment for men with prostate cancer

UCLA researchers have found that radiation therapy is the most common treatment for men with prostate cancer regardless of the aggressiveness of the tumor, risk to the patient and overall patient prognosis. These findings lay the groundwork for improved treatment assessment by physicians and to better inform men fighting the disease. [More]
Leaf Healthcare's wireless patient monitoring system can improve pressure ulcer prevention processes

Leaf Healthcare's wireless patient monitoring system can improve pressure ulcer prevention processes

Clinicians from the Veterans Affairs Medical Center in Boise, Idaho, will demonstrate that Leaf Healthcare's new, wireless patient monitoring system can significantly improve a caregiver's pressure ulcer prevention processes. Their presentation will take place at the National Pressure Ulcer Advisory Panel Biennial Conference in Orlando, Fla., this week. [More]
Findings may help doctors recommend appropriate treatments, improve patient outcomes

Findings may help doctors recommend appropriate treatments, improve patient outcomes

Like a car's front and back bumpers, your cell's chromosomes are capped by "telomeres" that protect this genetic material against deterioration. Still, after enough replications, a chromosome's telomeres break down and once they reach a certain point of degradation, the cell dies. This is one reason that cells are mortal: telomeres only last so long. That is, unless the enzyme telomerase builds new material onto the worn telomeres to reinforce these chromosomal "bumpers". Telomere repair can be a good thing, but in some cases it's not: overactive telomerase can lengthen telomeres until a cell becomes immortal…leading to cancer. [More]
Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S. [More]
Cabazitaxel therapy may be more effective in treating prostate cancer

Cabazitaxel therapy may be more effective in treating prostate cancer

Prostate cancer is the second leading cause of cancer for men in the United States. Only one class of chemotherapy called taxanes is effective against the disease. [More]
Actavis releases generic version of Pulmicort RESPULES

Actavis releases generic version of Pulmicort RESPULES

Actavis plc today announced that it has launched its generic version of AstraZeneca's Pulmicort RESPULES® (budesonide inhalation suspension) 0.25 and 0.5 mg vials following a ruling from the United States District Court for the District of New Jersey that (i) United States Patent No. 7,524,834 is invalid, and (ii) AstraZeneca's request for a permanent injunction is denied. [More]
Sanford Health wins LocumTenens.com's Best Places to Practice Locum Tenens contest

Sanford Health wins LocumTenens.com's Best Places to Practice Locum Tenens contest

Sanford Health, the nation's largest rural, not-for-profit healthcare system, has been named the winner of LocumTenens.com's Best Places to Practice Locum Tenens contest. [More]
GenomeDx announces publication of positive validation study for Decipher Prostate Cancer Classifier

GenomeDx announces publication of positive validation study for Decipher Prostate Cancer Classifier

GenomeDx Biosciences today announced the publication of a positive validation study for the Decipher® Prostate Cancer Classifier, a genomic test for prostate cancer. The study, published in the Journal of Clinical Oncology, showed that patients with low genomic risk (as determined by Decipher) may be optimally managed with observation after radical prostatectomy (prostate surgery), while those with high genomic risk (as determined by Decipher) may be better managed earlier with adjuvant radiotherapy. [More]